NCT04050176View on ClinicalTrials.gov

Use of Blinded Tapering for Hypnotic Discontinuation

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

260

Participants

Timeline

Start Date

December 16, 2019

Primary Completion Date

December 31, 2024

Study Completion Date

June 30, 2026

Conditions
Hypnotic Dependence Among Those With Insomnia
Interventions
BEHAVIORAL

Hypnotic Medication Open-Label Taper

Participants will have their soporific hypnotic medication dosage reduced by 25% every two weeks during a 10 week open-label tapering period.

BEHAVIORAL

Hypnotic Medication Blinded Taper

Participants will have their soporific hypnotic medication dosage reduced by 25% every two weeks during a 10 week blinded tapering period.

Trial Locations (1)

80206

National Jewish Health, Denver

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

National Jewish Health

OTHER

NCT04050176 - Use of Blinded Tapering for Hypnotic Discontinuation | Biotech Hunter | Biotech Hunter